Otsuka-Click alliance on digital therapeutics to help MDD patients
Category: #health  By Saipriya Iyer  Date: 2019-01-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

Otsuka-Click alliance on digital therapeutics to help MDD patients

Otsuka America, Inc., and Click Therapeutics, Inc., have reportedly announced that they have signed an agreement to develop and commercialize a digital therapeutic for the treatment of MDD. The partnership aims to provide medical assistance to MDD patients, the needs of whom remain unmet, and improve their mental health condition.

Reportedly, this collaboration will leverage Click’s potential to discover and validate a software application for commercial deployment, with the help of Otsuka’s expertise in developing prescription therapies for patients afflicted with serious mental illnesses. Apparently, both the companies believe that digital therapeutics align with psychiatry naturally, and have the capability to transform mental healthcare. By working together, both the companies intend to bring a new offering to the market that will provide a novel treatment for patients with Major Depressive Disorder (MDD).

Reliable sources state that Otsuka has agreed to fund the development of Click’s novel mobile application ‘CT-152’ for Major Depressive Disorder, and commercialize the same worldwide after obtaining regulatory approvals. Otsuka will pay $10 million upfront in regulatory milestone payments, and $20 million in development funding. Additionally, Otsuka will pay $272 million in commercial milestone payments based on regulatory approvals. Click will also receive royalties based on global sales of the software and the digital therapeutic applications.

Kabir Nath, President & CEO, Otsuka North America Pharmaceutical Business Division, Otsuka America, was reportedly quoted stating that this collaboration signifies Otsuka’s commitment to meet medical needs of the patients by developing innovative solutions beyond conventional medication. The firm’s goal is to provide evidence-driven cognitive therapies to a wide range of patients who are undergoing MDD, amid the challenges of a shortage of mental health professionals and less time to conduct cognitive therapy.

Nath added that the company is proud to be one of the few pharmaceutical firms that invests in developing medicinal and digital products for treating mental disorders. Otsuka is breaking barriers, he says, collaborating with top notch therapeutic technology firms like Click that have a similar vision as its own.



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Vela Diagnostics gains EUA for ViroKey™ SARS-CoV-2 RT-PCR test v2.0
Vela Diagnostics gains EUA for ViroKey™ SARS-CoV-2 RT-PCR test v2.0
By Saipriya Iyer

Vela Diagnostics has recently announced that the U.S. FDA has granted an EUA (Emergency Use Authorization) for its ViroKey™ SARS-CoV-2 RT-PCR Test v2.0 in the United States. This automated p...

Foodics enters Egypt market by setting an on-ground presence in Cairo
Foodics enters Egypt market by setting an on-ground presence in Cairo
By Saipriya Iyer

Saudi Arabia-based restaurant management platform Foodics, has announced that it has entered the Egyptian market by creating an on-the-ground presence in Cairo.  The expansion comes after the company raised USD 4 ...

Food Emulsifiers Market to Witness an Appreciable Growth By 2026
Food Emulsifiers Market to Witness an Appreciable Growth By 2026
By Saipriya Iyer

This advanced report on the Food Emulsifiers Market includes of an in-depth overview of this business sphere. Alongside, details of the present market size and status have been given. The report aims to provide substantial updates on the market, p...